摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-(S)-5-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one | 1408087-82-0

中文名称
——
中文别名
——
英文名称
(-)-(S)-5-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one
英文别名
5-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one;5-fluoro-3-(3-fluorophenyl)-2-[(1S)-1-hydroxyethyl]chromen-4-one
(-)-(S)-5-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one化学式
CAS
1408087-82-0
化学式
C17H12F2O3
mdl
——
分子量
302.277
InChiKey
ABSWWOAJWQZCQK-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    453.5±45.0 °C(Predicted)
  • 密度:
    1.381±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS
    申请人:Rhizen Pharmaceutical SA
    公开号:US20150087699A1
    公开(公告)日:2015-03-26
    The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    本发明涉及作为药物中间体有用的化合物,用于制备中间体的过程,用于这些过程中使用的中间体,以及在制备药物中使用这些中间体。具体来说,本发明涉及对映纯的可选取代的2-(1-羟基-烷基)-香豆素衍生物,其表示为式(IA)和(IB),制备醇衍生物的过程以及它们在制备药物中的使用。
  • PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS
    申请人:Rhizen Pharmaceuticals SA
    公开号:US20170266196A1
    公开(公告)日:2017-09-21
    The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    本发明涉及用作制药中间体的化合物,制备中间体的过程,用于过程的中间体以及中间体在制备制药品中的应用。特别地,本发明涉及旋光纯的可选取代的2-(1-羟基-烷基)-香豆素衍生物,其化学式为(IA)和(IB),制备醇衍生物的过程以及它们在制备制药品中的应用。
  • Compounds as modulators of protein kinases
    申请人:Rhizen Pharmaceuticals SA
    公开号:US10220035B2
    公开(公告)日:2019-03-05
    The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    本发明提供了 PI3K 蛋白激酶调节剂、制备方法、含有这些调节剂的药物组合物以及用它们治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
  • Substituted chromenones as modulators of protein kinases
    申请人:Rhizen Pharmaceuticals SA
    公开号:US10322130B2
    公开(公告)日:2019-06-18
    The present invention provides PI3K protein kinase modulators of formula wherein R, Cy1, R1, R2, L1 and Cy2 are as defined herein. The present invention also relates to methods of preparing compounds of formula (I) to pharmaceutical compositions containing them and to methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    本发明提供式 PI3K 蛋白激酶调节剂,其中 R、Cy1、R1、R2、L1 和 Cy2 如本文所定义。 本发明还涉及制备式(I)化合物的方法、含有式(I)化合物的药物组合物以及用式(I)化合物治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
  • Intermediates useful in the synthesis of compounds as modulators of protein kinases
    申请人:Rhizen Pharmaceuticals SA
    公开号:US11020399B2
    公开(公告)日:2021-06-01
    The present invention provides compounds of formula (10), formula (12), formula (14) and formula (15) wherein R, R1, R2, Cy1 and X are as described herein.
    本发明提供了式(10)、式(12)、式(14)和式(15)化合物 其中 R、R1、R2、Cy1 和 X 如本文所述。
查看更多